Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma IGI Presents 1st Clinical Data from Ph 1 Study of Trispecific Antibody, ISB 2001, Showing High ORR & Favorable Safety Profile in Heavily Treated RRMM Pts.

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting IGI Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma at ASH

IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma Preclinical data in Nature Cancer showed IGI's ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity